Brief: Prestige Biopharma Receives Final Market Approval From The European Commission For Drug ‘Tuznue,’ For The Treatment Of Breast Cancer And Metastatic Gastric Cancer
23/09/2024 03:11
Prestige Biopharma Ltd 950210.KS :
* PRESTIGE BIOPHARMA: RECEIVES FINAL MARKET APPROVAL FROM
THE
EUROPEAN COMMISSION FOR DRUG ‘TUZNUE,’ FOR THE TREATMENT OF
BREAST CANCER AND METASTATIC GASTRIC CANCER
Source text for Eikon: ID:
Further company coverage: 950210.KS
Recent news on Prestige Biopharma
See all newsBrief: Prestige Biopharma Wins 2 Billion Won Order
Brief: Prestige Biopharma Receives Final Market Approval From The European Commission For Drug ‘Tuznue,’ For The Treatment Of Breast Cancer And Metastatic Gastric Cancer
Australia's Imagion Biosystems rises on MOU for cancer detection device
Brief: Prestige Biopharma And Intas Pharmaceuticals Announce Partnership To Commercialize Bevacizumab Biosimilar
Brief: Prestige Biopharma Signs Pharmaceutical Contract Manufacturing Agreement With Benevira Inc